Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine, 277 Yanta West Road, Shaanxi, Xi'an 710061, People's Republic of China.
Endocrinology. 2011 Mar;152(3):1165-71. doi: 10.1210/en.2010-0737. Epub 2011 Feb 1.
Graves' disease is a common organ-specific autoimmune disease. The identity of its autoantigen, the TSH receptor (TSHR), was established and used to induce a typical animal model. A-subunit, the shed portion of TSHR, either initiates or amplifies the autoimmune response of the thyroid gland, thereby causing Graves' disease in humans. In the present study, we investigate the effect of the TSHR A-subunit on the induction of murine neonatal tolerance for the development of Graves' disease. Female BALB/c mice were pretreated with different doses of adenovirus expressing the A-subunit of TSHR (Ad-TSHR289) by either ip or im injection within the first 24 h after their birth. Graves' disease was induced after the animals reached adulthood. Nearly all mice pretreated with the high dose of Ad-TSHR289 failed to develop TSHR antibodies, detected by the TSH-binding inhibition assay, hyperthyroidism, and thyroid follicular hyperplasia. The mice preimmunized im with the lower doses of Ad-TSHR289 developed a relatively low level of TSH-binding inhibition and the low incidence of hyperthyroidism. Accordingly, the percentages of splenic CD4+CD25+/CD4+ and CD25+Foxp3+/CD4+ Treg cells were increased in mice pretreated with the high dose of Ad-TSHR289. Taken together, our data strongly indicate that the immunotolerance against Graves' disease could be induced in neonatal mice using a specific TSHR antigen in a high dose either by ip or im injection, preventing the development of Graves' disease.
格雷夫斯病是一种常见的器官特异性自身免疫性疾病。其自身抗原——促甲状腺激素受体(TSHR)的身份已被确定,并被用于诱导典型的动物模型。TSHR 的 A 亚基(TSHR A-subunit),即 TSHR 的脱落部分,要么引发要么放大甲状腺的自身免疫反应,从而导致人类患上格雷夫斯病。在本研究中,我们研究了 TSHR A 亚基对诱导新生小鼠对格雷夫斯病产生免疫耐受的影响。通过在出生后 24 小时内通过腹腔内或肌肉内注射不同剂量的表达 TSHR A 亚基的腺病毒(Ad-TSHR289)预处理雌性 BALB/c 小鼠。在动物成年后诱导格雷夫斯病。几乎所有用高剂量 Ad-TSHR289 预处理的小鼠都未能产生 TSH 结合抑制试验检测到的 TSHR 抗体、甲状腺功能亢进和甲状腺滤泡增生。用较低剂量的 Ad-TSHR289 经肌肉内预先免疫的小鼠产生相对较低水平的 TSH 结合抑制和较低的甲状腺功能亢进发生率。因此,用高剂量的 Ad-TSHR289 预处理的小鼠脾 CD4+CD25+/CD4+和 CD25+Foxp3+/CD4+Treg 细胞的百分比增加。总之,我们的数据强烈表明,使用高剂量的特异性 TSHR 抗原通过腹腔内或肌肉内注射可在新生小鼠中诱导针对格雷夫斯病的免疫耐受,从而防止格雷夫斯病的发生。